Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Controversies in Pathology

Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?

Abstract

In managing patients with solid tumors, the value of detecting the status of tumor DNA mismatch repair function is widely recognized. Mismatch repair protein immunohistochemistry and molecular microsatellite instability testing constitute the two major test modalities currently in use, yet each is associated with caveats and limitations that can be consequential. Most notably, the traditional approach of defining mismatch repair protein immunohistochemistry abnormality by complete loss of staining in all tumor cells is evolving. Partial or clonal loss is becoming recognized as a manifestation of gene abnormality; in some cases, such clonal loss is associated with germline pathogenic variants. The current criteria and cutoff values for defining microsatellite instability-high are developed primarily according to colorectal tumors. Non-colorectal cases, and occasionally even colorectal tumors, that are mismatch repair-deficient by immunohistochemistry but not microsatellite instability-high by current standards are being recognized. Emerging data suggest that these immunohistochemistry abnormal / non-microsatellite instability-high cases warrant further genetic workup for Lynch syndrome detection. Whether these tumors respond to immunotherapy is a question still to be addressed. It is imperative that pathologists as well as clinicians and investigators be aware of such intricacies regarding routine immunohistochemistry and microsatellite instability testing and the results they generate. This review summarizes our current understanding of the advantages and limitations of these tests and offer our view on what constitutes the most optimal strategy in test selection and how best to utilize case context to enhance the interpretation of the test results.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Interpretation of atypical MLH1 immunohistochemistry can be facilitated by the addition of PMS2 immunohistochemistry.
Fig. 2: A colorectal adenocarcinoma with distinct MSH6 clonal loss by immunohistochemistry in a patient who was found to have a germline pathogenic variant in MSH6.
Fig. 3: Two colorectal adenocarcinomas showing distinct clonal loss of specific mismatch repair proteins by immunohistochemistry.
Fig. 4: Examples of mismatch repair protein immunohistochemical staining variability.
Fig. 5: Representative electropherograms of the Promega MSI Analysis System showing MSI-high by PCR and fragment analysis.
Fig. 6: A stepwise approach for detecting loss of mismatch repair (MMR) in solid neoplasms.

References

  1. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58, 5248–5257 (1998).

  2. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336–1338 (1995).

  3. Abe T, Ouyang H, Migita T, Kato Y, Kimura M, Shiiba K et al. The somatic mutation frequency of the transforming growth factor beta receptor type II gene varies widely among different cancers with microsatellite instability. Eur J Surg Oncol 22, 474–477 (1996).

  4. Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL et al. The context-specific role of germline pathogenicity in tumorigenesis. Nat Genet 53, 1577–1585 (2021).

  5. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96, 261–268 (2004).

  6. Saeterdal I, Gjertsen MK, Straten P, Eriksen JA & Gaudernack G. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother 50, 469–476 (2001).

  7. Jardim DL, Goodman A, de Melo Gagliato D & Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154–173 (2021).

  8. Bruegl AS, Ring KL, Daniels M, Fellman BM, Urbauer DL & Broaddus RR. Clinical challenges associated with universal screening for Lynch syndrome-associated endometrial cancer. Cancer Prev Res (Phila) 10, 108–115 (2017).

  9. Dedeurwaerdere F, Claes KB, Van Dorpe J, Rottiers I, Van der Meulen J, Breyne J et al. Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci Rep 11, 12880 (2021).

  10. Bartley AN, Luthra R, Saraiya DS, Urbauer DL & Broaddus RR. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila) 5, 320–327 (2012).

  11. Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 125, 414–420 (2012).

  12. Siemanowski J, Schomig-Markiefka B, Buhl T, Haak A, Siebolts U, Dietmaier W et al. Managing difficulties of microsatellite instability testing in endometrial cancer-limitations and advantages of four different PCR-based approaches. Cancers (Basel) 13, 1268 (2021).

  13. Velasco A, Tokat F, Bonde J, Trim N, Bauer E, Meeney A et al. Multi-center real-world comparison of the fully automated Idylla microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer. Virchows Arch 478, 851–863 (2021).

  14. Yamamoto H & Imai K. An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. Semin Oncol 46, 261–270 (2019).

  15. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 10, 293–300 (2008).

  16. Hechtman JF, Rana S, Middha S, Stadler ZK, Latham A, Benayed R et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod Pathol 33, 871–879 (2020).

  17. Shia J. The diversity of tumours with microsatellite instability: molecular mechanisms and impact upon microsatellite instability testing and mismatch repair protein immunohistochemistry. Histopathology 78, 485–497 (2021).

  18. Singh N, Wong R, Tchrakian N, Allen S, Clarke B, Gilks CB. Interpretation and reporting terminology for mismatch repair protein immunohistochemistry in endometrial cancer, [Internet]. The British Association of Gynaecological Pathologists, 2020. Available from https://www.thebagp.org/resources/

  19. Singh N, Wong R, Tchrakian N, Allen SG, Clarke B & Gilks CB. Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. Mod Pathol 2020; 33:871–879. Mod Pathol 34, 1031–1032 (2021).

  20. Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 33, 1639–1645 (2009).

  21. Dong L, Zou S, Jin X, Lu H, Zhang Y, Guo L et al. Cytoplasmic MSH2 related to genomic deletions in the MSH2/EPCAM genes in colorectal cancer patients with suspected Lynch syndrome. Front Oncol 11, 627460 (2021).

  22. Sekine S, Ogawa R, Saito S, Ushiama M, Shida D, Nakajima T et al. Cytoplasmic MSH2 immunoreactivity in a patient with Lynch syndrome with an EPCAM-MSH2 fusion. Histopathology 70, 664–669 (2017).

  23. de Jong AE, van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, Ausems MG et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin. Cancer Res 10, 972–980 (2004).

  24. Shia J, Zhang L, Shike M, Guo M, Stadler Z, Xiong X et al. Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol 26, 131–138 (2013).

  25. Bao F, Panarelli NC, Rennert H, Sherr DL & Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol 34, 1798–1804 (2010).

  26. Chen W, Hampel H, Pearlman R, Jones D, Zhao W, Alsomali M et al. Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome. Hum Pathol 103, 34–41 (2020).

  27. Shia J, Stadler Z, Weiser MR, Rentz M, Gonen M, Tang LH et al. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? Am J Surg Pathol 35, 447–454 (2011).

  28. Longacre TA, Broaddus R, Chuang LT, Cohen MB, Jarboe EA, Mutter GL et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med 141, 1508–1512 (2017).

  29. Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy, [Internet]. Roche, 2021, [cited 7 May 2022]. Available from https://www.roche.com/media/releases/med-cor-2021-08-18

  30. VENTANA MMR RxDx Panel – P210001, [Internet]. Food and Drug Administration, 2011, [cited 7 May 2022]. Available from https://www.fda.gov/medical-devices/recently-approved-devices/ventana-mmr-rxdx-panel-p210001

  31. McCarthy AJ, Capo-Chichi JM, Spence T, Grenier S, Stockley T, Kamel-Reid S et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res 5, 115–129 (2019).

  32. Joost P, Veurink N, Holck S, Klarskov L, Bojesen A, Harbo M et al. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol 9, 126 (2014).

  33. Tachon G, Frouin E, Karayan-Tapon L, Auriault ML, Godet J, Moulin V et al. Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. Eur J Cancer 95, 112–116 (2018).

  34. Sari A, Pollett A, Eiriksson LR, Lumsden-Johanson B, Van de Laar E, Kazerouni H et al. Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas. Am J Surg Pathol 43, 591–600 (2019).

  35. Casey L & Singh N. POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. Int J Gynecol Pathol 40, 5–16 (2021).

  36. Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol 28, 96–102 (2017).

  37. Bai Z, Zhou Y, Ye Z, Xiong J, Lan H & Wang F. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. Front Immunol 12, 808964 (2021).

  38. How-Kit A, Daunay A, Buhard O, Meiller C, Sahbatou M, Collura A et al. Major improvement in the detection of microsatellite instability in colorectal cancer using HSP110 T17 E-ice-COLD-PCR. Hum Mutat 39, 441–453 (2018).

  39. Ladas I, Yu F, Leong KW, Fitarelli-Kiehl M, Song C, Ashtaputre R et al. Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies. Nucleic Acids Res 46, e74 (2018).

  40. Baudrin LG, Duval A, Daunay A, Buhard O, Bui H, Deleuze JF et al. Improved microsatellite instability detection and identification by nuclease-assisted microsatellite instability enrichment using HSP110 T17. Clin Chem 64, 1252–1253 (2018).

  41. Gilson P, Levy J, Rouyer M, Demange J, Husson M, Bonnet C et al. Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers. Sci Rep 10, 16386 (2020).

  42. Silveira AB, Bidard FC, Kasperek A, Melaabi S, Tanguy ML, Rodrigues M et al. High-accuracy determination of microsatellite instability compatible with liquid biopsies. Clin Chem 66, 606–613 (2020).

  43. Pan KF, Liu W, Lu YY, Zhang L, Li ZP, Lu WL et al. High throughput detection of microsatellite instability by denaturing high-performance liquid chromatography. Hum Mutat 22, 388–394 (2003).

  44. Janavicius R, Matiukaite D, Jakubauskas A & Griskevicius L. Microsatellite instability detection by high-resolution melting analysis. Clin Chem 56, 1750–1757 (2010).

  45. Bacher JW, Sievers CK, Albrecht DM, Grimes IC, Weiss JM, Matkowskyj KA et al. Improved detection of microsatellite instability in early colorectal lesions. PLoS One 10, e0132727 (2015).

  46. Wu S, Liu X, Wang J, Zhou W, Guan M, Liu Y et al. DNA mismatch repair deficiency detection in colorectal cancer by a new microsatellite instability analysis system. Interdiscip Sci 12, 145–154 (2020).

  47. Pecriaux A, Favre L, Calderaro J, Charpy C, Derman J & Pujals A. Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA. J Clin Pathol 74, 36–42 (2021).

  48. Lin JH, Chen S, Pallavajjala A, Guedes LB, Lotan TL, Bacher JW et al. Validation of long mononucleotide repeat markers for detection of microsatellite instability. J Mol Diagn 24, 144–157 (2022).

  49. Buhard O, Lagrange A, Guilloux A, Colas C, Chouchene M, Wanherdrick K et al. HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. J Med Genet 53, 377–384 (2016).

  50. Gilson P, Merlin JL & Harle A. Detection of microsatellite instability: state of the art and future applications in circulating tumour DNA (ctDNA). Cancers (Basel) 13, 1491 (2021).

  51. Zwaenepoel K, Holmgaard Duelund J, De Winne K, Maes V, Weyn C, Lambin S et al. Clinical performance of the Idylla MSI test for a rapid assessment of the DNA microsatellite status in human colorectal cancer. J Mol Diagn 22, 386–395 (2020).

  52. Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30, 1232–1243 (2019).

  53. Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31, 861–872 (2020).

  54. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015–1016 (2014).

  55. Huang MN, McPherson JR, Cutcutache I, Teh BT, Tan P & Rozen SG. MSIseq: software for assessing microsatellite instability from catalogs of somatic mutations. Sci Rep 5, 13321 (2015).

  56. Hause RJ, Pritchard CC, Shendure J & Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22, 1342–1350 (2016).

  57. Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget 8, 7452–7463 (2017).

  58. Cortes-Ciriano I, Lee S, Park WY, Kim TM & Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 8, 15180 (2017).

  59. Han X, Zhang S, Zhou DC, Wang D, He X, Yuan D et al. MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data. Brief Bioinform 22, bbaa402 (2021).

  60. Ziegler J, Hechtman JF, Ptashkin R, Jayakumaran G, Middha S, Chavan SS et al. MiMSI - a deep multiple instance learning framework improves microsatellite instability detection from tumor next-generation sequencing. bioRxiv (2022). https://doi.org/10.1101/2020.09.16.299925

  61. Salipante SJ, Scroggins SM, Hampel HL, Turner EH & Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 60, 1192–1199 (2014).

  62. Foltz SM, Liang WW, Xie M & Ding L. MIRMMR: binary classification of microsatellite instability using methylation and mutations. Bioinformatics 33, 3799–3801 (2017).

  63. Wang C & Liang C. MSIpred: a python package for tumor microsatellite instability classification from tumor mutation annotation data using a support vector machine. Sci Rep 8, 17546 (2018).

  64. Zhu L, Huang Y, Fang X, Liu C, Deng W, Zhong C et al. A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing. J Mol Diagn 20, 225–231 (2018).

  65. Escudie F, Van Goethem C, Grand D, Vendrell J, Vigier A, Brousset P et al. MIAmS: microsatellite instability detection on NGS amplicons data. Bioinformatics 36, 1915–1916 (2019).

  66. Pang J, Gindin T, Mansukhani M, Fernandes H & Hsiao S. Microsatellite instability detection using a large next-generation sequencing cancer panel across diverse tumour types. J Clin Pathol 73, 83–89 (2020).

  67. Jia P, Yang X, Guo L, Liu B, Lin J, Liang H et al. MSIsensor-pro: fast, accurate, and matched-normal-sample-free detection of microsatellite instability. Genomics Proteomics Bioinformatics 18, 65–71 (2020).

  68. Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol 1, PO.17.00084 (2017).

  69. Kuismanen SA, Moisio AL, Schweizer P, Truninger K, Salovaara R, Arola J et al. Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 160, 1953–1958 (2002).

  70. Xicola RM, Llor X, Pons E, Castells A, Alenda C, Pinol V et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99, 244–252 (2007).

  71. Palomaki GE, McClain MR, Melillo S, Hampel HL & Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11, 42–65 (2009).

  72. Baudrin LG, Deleuze JF & How-Kit A. Molecular and computational methods for the detection of microsatellite instability in cancer. Front Oncol 8, 621 (2018).

  73. Evrard C, Tachon G, Randrian V, Karayan-Tapon L & Tougeron D. Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. Cancers (Basel) 11, 1567 (2019).

  74. Schwartz CJ, da Silva EM, Marra A, Gazzo AM, Selenica P, Rai VK et al. Morphological and genomic characteristics of breast cancers occurring in individuals with Lynch Syndrome. Clin Cancer Res 28, 404–413 (2022).

  75. Vyas M, Firat C, Hechtman JF, Weiser MR, Yaeger R, Vanderbilt C et al. Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Fam Cancer 20, 201–213 (2021).

  76. Karamurzin Y, Zeng Z, Stadler ZK, Zhang L, Ouansafi I, Al-Ahmadie HA et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol 43, 1677–1687 (2012).

  77. Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37, 286–295 (2019).

  78. Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485–491 (2019).

  79. Provenzale D, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G et al. Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14, 1010–1030 (2016).

  80. Ryan N, Wall J, Crosbie EJ, Arends M, Bosse T, Arif S et al. Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology 75, 813–824 (2019).

  81. Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol 5, 551–555 (2019).

Download references

Acknowledgements

We thank Dr. Cyriac Kandoth (Director, Clinical Bioinformatics, Molecular Diagnostics at UCLA) for his expert guidance on the NGS-based MSI detection methods.

Author information

Authors and Affiliations

Authors

Contributions

JS conceived the review manuscript. All authors participated in reviewing the literature and drafting the manuscript. JS and CW revised the final manuscript which was approved by all authors.

Corresponding author

Correspondence to Jinru Shia.

Ethics declarations

Competing interests

JS discloses the following relationship: Consultant, Paige.AI, Inc. LZ discloses the following relationship: Family members hold leadership positions and ownership interests in Decipher Medicine. CW: None. EV: None.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Zhang, L., Vakiani, E. et al. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?. Mod Pathol (2022). https://doi.org/10.1038/s41379-022-01109-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41379-022-01109-4

Search

Quick links